Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2006;99:442-450
Published online before print July 20, 2006, doi: 10.1161/01.RES.0000237390.92932.37
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
99/4/442    most recent
01.RES.0000237390.92932.37v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seubert, J. M.
Right arrow Articles by Zeldin, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seubert, J. M.
Right arrow Articles by Zeldin, D. C.
Related Collections
Right arrow Animal models of human disease
Right arrow Ischemic biology - basic studies
(Circulation Research. 2006;99:442.)
© 2006 American Heart Association, Inc.


Integrative Physiology

Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function

John M. Seubert*, Christopher J. Sinal*, Joan Graves, Laura M. DeGraff, J. Alyce Bradbury, Craig R. Lee, Kerry Goralski, Michelle A. Carey, Ayala Luria, John W. Newman, Bruce D. Hammock, John R. Falck, Holly Roberts, Howard A. Rockman, Elizabeth Murphy, Darryl C. Zeldin

From the Faculty of Pharmacy and Pharmaceutical Sciences (J.M.S.), University of Alberta, Edmonton, AB, Canada; the Division of Intramural Research (J.M.S., J.G., L.M.D., J.A.B., C.R.L., M.A.C., E.M., D.C.Z.), NIEHS/NIH, Research Triangle Park, NC; the Department of Pharmacology (C.J.S., K.G.), Dalhousie University, Halifax, NS, Canada; the Department of Entomology and Cancer Research Center (A.L., J.W.N., B.D.H.), University of California, Davis, Calif; the Departments of Biochemistry and Pharmacology (J.R.F.), University of Texas Southwestern Medical Center, Dallas, Tex; the Department of Medicine (H.R., H.A.R., D.C.Z.), Duke University Medical Center, Durham, NC; and the School of Pharmacy (C.R.L.), University of North Carolina at Chapel Hill, Chapel Hill, NC.

Correspondence to Darryl C. Zeldin, MD, National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709. E-mail zeldin{at}niehs.nih.gov

Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which are converted to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (Ephx2, sEH). To examine the functional role of sEH in the heart, mice with targeted disruption of the Ephx2 gene were studied. Hearts from sEH null mice have undetectable levels of sEH mRNA and protein and cannot convert EETs to DHETs. sEH null mice have normal heart anatomy and basal contractile function, but have higher fatty acid epoxide:diol ratios in plasma and cardiomyocyte cell culture media compared with wild type (WT). sEH null hearts have improved recovery of left ventricular developed pressure (LVDP) and less infarction compared with WT hearts after 20 minutes ischemia. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (10 to 100 nmol/L) before ischemia abolishes this cardioprotective phenotype. Inhibitor studies demonstrate that perfusion with phosphatidylinositol-3 kinase (PI3K) inhibitors wortmannin (200 nmol/L) or LY294002 (5 µmol/L), the ATP-sensitive K+ channel (KATP) inhibitor glibenclamide (1 µmol/L), the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (100 to 200 µmol/L), or the Ca2+-sensitive K+ channel (KCa) inhibitor paxilline (10 µmol/L) abolishes the cardioprotection in sEH null hearts. Consistent with increased activation of the PI3K cascade, sEH null mice exhibit increased cardiac expression of glycogen synthase kinase-3ß (GSK-3ß) phospho-protein after ischemia. Together, these data suggest that targeted disruption of sEH increases the availability of cardioprotective EETs that work by activating PI3K signaling pathways and K+ channels.


Key Words: arachidonic acid • cytochrome P450 • eicosanoid • ischemia/reperfusion




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. J. Merkel, L. Liu, Z. Cao, W. Packwood, J. Young, N. J. Alkayed, and D. M. Van Winkle
Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling
Am J Physiol Heart Circ Physiol, February 1, 2010; 298(2): H679 - H687.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Manhiani, J. E. Quigley, S. F. Knight, S. Tasoobshirazi, T. Moore, M. W. Brands, B. D. Hammock, and J. D. Imig
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension
Am J Physiol Renal Physiol, September 1, 2009; 297(3): F740 - F748.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. R. Chaudhary, S. N. Batchu, D. Das, M. R. Suresh, J. R. Falck, J. P. Graves, D. C. Zeldin, and J. M. Seubert
Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function
Cardiovasc Res, July 15, 2009; 83(2): 362 - 370.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Zhang, H. El-Sikhry, K. R. Chaudhary, S. N. Batchu, A. Shayeganpour, T. O. Jukar, J. A. Bradbury, J. P. Graves, L. M. DeGraff, P. Myers, et al.
Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H37 - H46.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. N. Simpkins, R. D. Rudic, D. A. Schreihofer, S. Roy, M. Manhiani, H.-J. Tsai, B. D. Hammock, and J. D. Imig
Soluble Epoxide Inhibition Is Protective Against Cerebral Ischemia via Vascular and Neural Protection
Am. J. Pathol., June 1, 2009; 174(6): 2086 - 2095.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Ai, W. Pang, N. Li, M. Xu, P. D. Jones, J. Yang, Y. Zhang, N. Chiamvimonvat, J. Y.-J. Shyy, B. D. Hammock, et al.
Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy
PNAS, January 13, 2009; 106(2): 564 - 569.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. J. Behm, A. Ogbonna, C. Wu, C. L. Burns-Kurtis, and S. A. Douglas
Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation
J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 231 - 239.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. L. Fife, Y. Liu, K. R. Schmelzer, H.-J. Tsai, I.-H. Kim, C. Morisseau, B. D. Hammock, and D. L. Kroetz
Inhibition of Soluble Epoxide Hydrolase Does Not Protect against Endotoxin-Mediated Hepatic Inflammation
J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 707 - 715.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Motoki, M. J. Merkel, W. H. Packwood, Z. Cao, L. Liu, J. Iliff, N. J. Alkayed, and D. M. Van Winkle
Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo
Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2128 - H2134.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. Jiang, A. G. Zhu, M. Mamczur, C. Morisseau, B. D. Hammock, J. R. Falck, and J. C. McGiff
Hydrolysis of cis- and trans-Epoxyeicosatrienoic Acids by Rat Red Blood Cells
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 330 - 337.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
W. Zhang, T. Otsuka, N. Sugo, A. Ardeshiri, Y. K. Alhadid, J. J. Iliff, A. E. DeBarber, D. R. Koop, and N. J. Alkayed
Soluble Epoxide Hydrolase Gene Deletion Is Protective Against Experimental Cerebral Ischemia
Stroke, July 1, 2008; 39(7): 2073 - 2078.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. J. Gross, K. M. Gauthier, J. Moore, J. R. Falck, B. D. Hammock, W. B. Campbell, and K. Nithipatikom
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2838 - H2844.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Dhanasekaran, S. K. Gruenloh, J. N. Buonaccorsi, R. Zhang, G. J. Gross, J. R. Falck, P. K. Patel, E. R. Jacobs, and M. Medhora
Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H724 - H735.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Q. Ke, Y.-F. Xiao, J. A. Bradbury, J. P. Graves, L. M. DeGraff, J. M. Seubert, and D. C. Zeldin
Electrophysiological Properties of Cardiomyocytes Isolated from CYP2J2 Transgenic Mice
Mol. Pharmacol., October 1, 2007; 72(4): 1063 - 1073.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. A. Spector and A. W. Norris
Action of epoxyeicosatrienoic acids on cellular function
Am J Physiol Cell Physiol, March 1, 2007; 292(3): C996 - C1012.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Luria, S. M. Weldon, A. K. Kabcenell, R. H. Ingraham, D. Matera, H. Jiang, R. Gill, C. Morisseau, J. W. Newman, and B. D. Hammock
Compensatory Mechanism for Homeostatic Blood Pressure Regulation in Ephx2 Gene-disrupted Mice
J. Biol. Chem., February 2, 2007; 282(5): 2891 - 2898.
[Abstract] [Full Text] [PDF]